A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
Clinical trial NCT07666555 · RECRUITING
Trial details
- NCT number
- NCT07666555
- Sponsor
- Fudan University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-06
- Primary completion
- 2028-06-30
- Enrollment
- 98
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.